NASDAQ: OTLKOutlook Therapeutics Inc Stock
$1.75+0.14 (+8.7%)
Updated Jun 5, 2023
OTLK Price
$1.75
Fair Value Price
$1.98
Market Cap
$449.17M
52 Week Low
$0.80
52 Week High
$1.90
P/E
-7x
P/B
42.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.15
Operating Cash Flow
-$48M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OTLK Overview
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OTLK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OTLK ($1.75) is undervalued by 11.62% relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
OTLK ($1.75) is not significantly undervalued (11.62%) relative to our estimate of its Fair Value price of $1.98 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OTLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OTLK due diligence checks available for Premium users.
Be the first to know about important OTLK news, forecast changes, insider trades & much more!
OTLK News
Valuation
OTLK fair value
Fair Value of OTLK stock based on Discounted Cash Flow (DCF)
Price
$1.75
Fair Value
$1.98
Undervalued by
11.62%
OTLK ($1.75) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OTLK ($1.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OTLK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OTLK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7x
Industry
11.59x
Market
53.21x
OTLK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
42.83x
Industry
5.21x
OTLK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OTLK's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.7M
Profit Margin
0%
OTLK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$54.0M
Liabilities
$43.5M
Debt to equity
4.15
OTLK's short-term assets ($53.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OTLK's short-term assets ($53.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OTLK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OTLK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.1M
Investing
$0.0
Financing
-$597.1k
OTLK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OTLK vs Biotech Stocks
Outlook Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.